OS Therapies (NYSEAMERICAN:OSTX) Releases Earnings Results

OS Therapies (NYSEAMERICAN:OSTX) issued its quarterly earnings data on Friday. The company reported ($0.20) earnings per share (EPS) for the quarter, FiscalAI reports.

OS Therapies Price Performance

OS Therapies stock opened at $1.62 on Friday. The stock’s fifty day moving average is $1.68 and its two-hundred day moving average is $1.57. The stock has a market cap of $73.77 million, a PE ratio of -1.49 and a beta of -0.73. OS Therapies has a 1-year low of $1.15 and a 1-year high of $2.57.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on OSTX shares. D. Boral Capital restated a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a report on Thursday, April 30th. Lake Street Capital decreased their price target on OS Therapies from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Zacks Research upgraded OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 4th. Finally, Roth Capital assumed coverage on OS Therapies in a report on Thursday, July 9th. They issued a “buy” rating and a $7.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.33.

Hedge Funds Weigh In On OS Therapies

Hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP acquired a new position in OS Therapies in the third quarter valued at $29,000. Jane Street Group LLC purchased a new stake in shares of OS Therapies in the 4th quarter valued at about $39,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of OS Therapies in the 3rd quarter valued at about $40,000. Bridgeway Capital Management LLC purchased a new position in OS Therapies during the 2nd quarter worth approximately $47,000. Finally, XTX Topco Ltd acquired a new position in OS Therapies during the second quarter worth approximately $63,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.